DOCS
Doximity’s little doctor-tech empire keeps growing
Doximity says it finished fiscal 2026 with a fresh engagement record: over 800,000 active prescribers used its workflow tools in Q4. That’s not exactly couch-cushion trivia. For a platform that sells into a notoriously busy, hard-to-reach crowd, getting doctors to actually use the product is the whole ballgame.
The AI angle is doing the heavy lifting
The company also said nearly half of those providers used its clinical AI last quarter, and prompts per user nearly doubled from January to April. In plain English: this isn’t just a shiny feature nobody touches after the demo. It looks like doctors are leaning on the tools more often, which could support stronger retention and give Doximity more room to upsell down the road.
Why investors should care
The market usually wants two things from software companies: growth and stickiness. Doximity is showing a little of both, at least on the usage side. If workflow tools and AI become part of the daily routine, that can be a very nice setup for revenue durability — the corporate version of “once you go here, you don’t go back.”
Big picture: Doximity doesn’t need to be the flashiest company in health tech. It just needs doctors to keep coming back, and on that front, the numbers look pretty healthy.